Related Experiment Video
Updated: Sep 4, 2025
Determination of Mitochondrial Respiration and Glycolysis in Ex Vivo Retinal Tissue Samples
Published on: August 4, 2021
Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor
Walter H Moos1, Douglas V Faller2, Ioannis P Glavas3
1Department of Pharmaceutical Chemistry, School of Pharmacy, University of California San Francisco, San Francisco, CA, USA.
Abstract:
Pathological deterioration of mitochondrial function is increasingly linked with multiple degenerative illnesses as a mediator of a wide range of neurologic and age-related chronic diseases, including those of genetic origin. Several of these diseases are rare, typically defined in the United States as an illness affecting fewer than 200,000 people in the U.S. population, or about one in 1600 individuals. Vision impairment due to mitochondrial dysfunction in the eye is a prominent feature evident in numerous primary mitochondrial diseases and is common to the pathophysiology of many of the familiar ophthalmic disorders, including age-related macular degeneration, diabetic retinopathy, glaucoma and retinopathy of prematurity - a collection of syndromes, diseases and disorders with significant unmet medical needs. Focusing on metabolic mitochondrial pathway mechanisms, including the possible roles of cuproptosis and ferroptosis in retinal mitochondrial dysfunction, we shed light on the potential of α-lipoyl-L-carnitine in treating eye diseases. α-Lipoyl-L-carnitine is a bioavailable mitochondria-targeting lipoic acid prodrug that has shown potential in protecting against retinal degeneration and photoreceptor cell loss in ophthalmic indications.
Insights
Mitochondrial dysfunction contributes to rare and common eye diseases. Alpha-lipoyl-L-carnitine shows promise in protecting retinal cells and treating vision impairment caused by these conditions.
Area of Science:
- Biochemistry
- Ophthalmology
- Neurodegenerative Diseases
Background:
- Mitochondrial dysfunction is implicated in numerous neurologic and age-related chronic diseases.
- Vision impairment is a key feature of primary mitochondrial diseases and common ophthalmic disorders like AMD, diabetic retinopathy, and glaucoma.
- Many of these conditions represent rare diseases with significant unmet medical needs.
Purpose of the Study:
- To investigate the role of metabolic mitochondrial pathways, including cuproptosis and ferroptosis, in retinal mitochondrial dysfunction.
- To explore the therapeutic potential of α-lipoyl-L-carnitine for treating eye diseases linked to mitochondrial dysfunction.
Main Methods:
- Focus on metabolic mitochondrial pathway mechanisms.
- Investigate the roles of cuproptosis and ferroptosis in retinal mitochondrial dysfunction.
- Evaluate the protective effects of α-lipoyl-L-carnitine in ophthalmic indications.
Main Results:
- α-Lipoyl-L-carnitine, a mitochondria-targeting lipoic acid prodrug, demonstrated potential in preclinical models.
- Evidence suggests its protective capacity against retinal degeneration and photoreceptor cell loss.
- The study sheds light on the mechanisms of retinal mitochondrial dysfunction.
Conclusions:
- α-Lipoyl-L-carnitine holds promise as a therapeutic agent for eye diseases associated with mitochondrial dysfunction.
- Targeting metabolic pathways offers a potential strategy for treating conditions like AMD, diabetic retinopathy, and glaucoma.
- Further research into lipoic acid prodrugs could address unmet needs in ophthalmology.
